Exelixis Inc
EXEL36.220USD
-0.635-1.72%
Fechamento 07/31, 16:00（ET）Cotações atrasadas em 15 min
9.78BValor de mercado
15.20P/L TTM
Mais detalhes de Exelixis Inc Empresa
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Informações da empresa
Código da empresaEXEL
Nome da EmpresaExelixis Inc
Data de listagemApr 11, 2000
Fundado em1994
CEODr. Michael M. Morrissey, Ph.D.
Número de funcionários1147
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 11
Endereço1851 Harbor Bay Parkway
CidadeALAMEDA
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94502
Telefone16508377000
Sitehttps://www.exelixis.com/
Código da empresaEXEL
Data de listagemApr 11, 2000
Fundado em1994
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.27M
-4.42%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.27M
+0.78%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
410.70K
-12.57%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
359.32K
-8.22%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
340.04K
-2.17%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
258.52K
-25.63%
Dr. George H. Poste, Ph.D.
Dr. George H. Poste, Ph.D.
Independent Director
Independent Director
159.99K
+6.53%
Dr. Amy C. Peterson, M.D.
Dr. Amy C. Peterson, M.D.
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
151.08K
-21.38%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
81.98K
+13.60%
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
10.57K
+1285.98%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.27M
-4.42%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.27M
+0.78%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
410.70K
-12.57%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
359.32K
-8.22%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
340.04K
-2.17%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
258.52K
-25.63%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
CABOMETYX
510.87M
91.97%
License revenues
42.48M
7.65%
COMETRIQ
2.41M
0.43%
Collaboration services revenues
-316.00K
-0.06%
Por RegiãoUSD
Nome
Receita
Proporção
U.S
517.18M
93.11%
Europe
32.71M
5.89%
Japan
5.56M
1.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
CABOMETYX
510.87M
91.97%
License revenues
42.48M
7.65%
COMETRIQ
2.41M
0.43%
Collaboration services revenues
-316.00K
-0.06%
Distribuição de ações
Atualizado em: qui, 22 de mai
Atualizado em: qui, 22 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.63%
BlackRock Institutional Trust Company, N.A.
9.84%
Farallon Capital Management, L.L.C.
6.92%
Renaissance Technologies LLC
5.51%
State Street Global Advisors (US)
4.38%
Other
62.72%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.63%
BlackRock Institutional Trust Company, N.A.
9.84%
Farallon Capital Management, L.L.C.
6.92%
Renaissance Technologies LLC
5.51%
State Street Global Advisors (US)
4.38%
Other
62.72%
Tipos de investidores
Investidores
Proporção
Investment Advisor
44.30%
Investment Advisor/Hedge Fund
26.92%
Hedge Fund
15.92%
Pension Fund
3.14%
Individual Investor
2.20%
Research Firm
1.98%
Sovereign Wealth Fund
1.28%
Bank and Trust
0.50%
Family Office
0.16%
Other
3.60%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
1059
262.65M
97.57%
-13.60M
2025Q1
1059
268.29M
98.20%
-10.58M
2024Q4
992
262.76M
93.66%
-11.36M
2024Q3
924
259.58M
90.96%
-10.18M
2024Q2
908
255.61M
87.75%
-22.29M
2024Q1
905
264.69M
87.26%
-20.82M
2023Q4
882
270.85M
87.07%
-16.64M
2023Q3
847
278.02M
87.32%
-18.15M
2023Q2
833
285.95M
87.85%
-21.34M
2023Q1
841
294.75M
90.97%
-14.08M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
28.61M
10.49%
-757.26K
-2.58%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
26.49M
9.71%
-219.09K
-0.82%
Mar 31, 2025
Farallon Capital Management, L.L.C.
18.64M
6.83%
-3.90M
-17.30%
May 16, 2025
Renaissance Technologies LLC
14.82M
5.44%
-471.60K
-3.08%
Mar 31, 2025
State Street Global Advisors (US)
11.79M
4.32%
+377.67K
+3.31%
Mar 31, 2025
LSV Asset Management
8.16M
2.99%
-8.51K
-0.10%
Mar 31, 2025
Fuller & Thaler Asset Management Inc.
7.80M
2.86%
+164.13K
+2.15%
Mar 31, 2025
Geode Capital Management, L.L.C.
7.42M
2.72%
+2.26M
+43.80%
Mar 31, 2025
AQR Capital Management, LLC
6.89M
2.53%
+2.93M
+73.78%
Mar 31, 2025
Invesco Capital Management LLC
4.61M
1.69%
+1.43M
+44.74%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Nome
Proporção
Adaptiv Select ETF
149.65%
Invesco Dorsey Wright Healthcare Momentum ETF
4.87%
Tema Oncology ETF
4.38%
iShares Genomics Immunology and Healthcare ETF
4.11%
First Trust NYSE Arca Biotechnology Index Fund
3.83%
Invesco Biotechnology & Genome ETF
3.38%
Burney US Factor Rotation ETF
2.79%
SPDR S&P Biotech ETF
2.68%
First Trust Health Care Alphadex Fund
2.65%
ERShares Entrepreneurs ETF
2.49%
Ver Mais
Adaptiv Select ETF
Proporção149.65%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporção4.87%
Tema Oncology ETF
Proporção4.38%
iShares Genomics Immunology and Healthcare ETF
Proporção4.11%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.83%
Invesco Biotechnology & Genome ETF
Proporção3.38%
Burney US Factor Rotation ETF
Proporção2.79%
SPDR S&P Biotech ETF
Proporção2.68%
First Trust Health Care Alphadex Fund
Proporção2.65%
ERShares Entrepreneurs ETF
Proporção2.49%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
